Fig. 6 | Oncogene

Fig. 6

From: Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells

Fig. 6

Treatment with Pac 1 inhibits PI4K2A expression and impairs lysosome function in cancer cells. a The half-maximal inhibitory concentration (IC50) of Pac 1 for PI4K2A kinase as determined by Reaction Biology Corp. using a high-throughput enzymatic assay. b Mechanism of action of PI4K2A on the AP-3 complex in cancer cells. ER endoplasmic reticulum. c Western blot of expression of AP-1, AP-2, and AP-3 complex-associated proteins in lung and breast cancer cells 72 h after treatment with 5 μM Pac 1 or Pac 2. Actin expression was used as a loading control (Con). d Protein fractions obtained from H1299 and MDA-MB-231 cells treated with PBS, Ad-Luc, Ad-Prion (2500 viral particles/cell), or Ad-Prion plus Pac 1 (5 μM) for 48 h were immunoprecipitated with antihuman PI4K2A and assayed for PKR or PI4K2A protein. e Differential scanning fluorimetry curve showing that Pac 1 bound to PI4K2A and caused a decrease in the melting temperature of PI4K2A protein

Back to article page